See up to 3 months of RPRX. The 7-day demo opens the 1M and 3M ranges and puts RPRX on your watchlist.
Start 7-day demoLatest RPRX insider trades
About Royalty Pharma plc (RPRX)
Royalty Pharma plc is an SEC registrant, filing under CIK 0001802768, classified as pharmaceutical preparations. It is grouped with Health Care companies on this site.
RPRX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 7 | 219,254 | $12.97M |
| Grant or award | 5 | 96,114 | |
| Bona-fide gift | 4 | 68,300 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
RPRX insider transactions (Form 4)
4069 Form 4 filings on record, the earliest from May 13, 2025, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Marshall Urist - Officer | Open-market sale | Class A Ordinary Shares | 4,126 | $57.10 | $236K | |
| Bonnie L. Bassler - Director | Grant or award | Class A Ordinary Shares | 642 | $58.41 footnote F1 | $37K | |
| ||||||
| Marshall Urist - Officer | Open-market sale | Class A Ordinary Shares | 4,126 | $57.88 | $239K | |
| Christopher Hite - Officer | Open-market sale | Class A Ordinary Shares | 96,073 | $58.51 footnote F2 | $5.62M | |
| Christopher Hite - Officer | Open-market sale | Class A Ordinary Shares | 3,927 | $58.93 footnote F3 | $231K | |
| ||||||
| Christopher Hite - Officer | Open-market sale | Class A Ordinary Shares | 100,000 | $59.97 footnote F2 | $6.00M | |
| Christopher Hite - Officer | Gift | Class A Ordinary Shares | 16,800 | $0.00 | - | |
| ||||||
| Terrance P. Coyne - Officer | Open-market sale | Class A Ordinary Shares | 9,230 | $58.59 footnote F2 | $541K | |
| Terrance P. Coyne - Officer | Open-market sale | Class A Ordinary Shares | 1,772 | $59.14 footnote F3 | $105K | |
| ||||||
| Grant or award | Class A Ordinary Shares | 65,216 footnote F1 | $0.00 | - | ||
| Gift | LP interests in RPI US Partners 2019, LP | 30,000 | $0.00 | - | ||
| ||||||
| Terrance P. Coyne - Officer | Grant or award | Class A Ordinary Shares | 11,002 footnote F1 | $0.00 | - | |
| Terrance P. Coyne - Officer | Gift | Class E Ordinary Shares | 18,500 | $0.00 | - | |
| ||||||
| Christopher Hite - Officer | Grant or award | Class A Ordinary Shares | 11,002 footnote F1 | $0.00 | - | |
| ||||||
| Marshall Urist - Officer | Grant or award | Class A Ordinary Shares | 8,252 footnote F1 | $0.00 | - | |
| Marshall Urist - Officer | Gift | LP interests in RPI US Partners 2019, LP | 3,000 | $0.00 | - | |
| ||||||
| Marshall Urist - Officer | Open-market sale | Class A Ordinary Shares | 9,099 | $55.88 footnote F2 | $508K | |
| ||||||
| Christopher Hite - Officer | Open-market sale | Class A Ordinary Shares | 97,446 | $56.50 footnote F2 | $5.51M | |
| Christopher Hite - Officer | Open-market sale | Class A Ordinary Shares | 2,554 | $57.10 footnote F3 | $146K | |
| Christopher Hite - Officer | Open-market sale | Class A Ordinary Shares | 29,400 | $56.44 footnote F4 | $1.66M | |
| Christopher Hite - Officer | Open-market sale | Class A Ordinary Shares | 600 | $57.09 footnote F5 | $34K | |
| ||||||
| Bonnie L. Bassler - Director | Grant or award | Class A Ordinary Shares | 689 | $54.40 footnote F1 | $37K | |
| ||||||
| Marshall Urist - Officer | Open-market sale | Class A Ordinary Shares | 9,098 | $55.18 footnote F2 | $502K | |
| ||||||
| Christopher Hite - Officer | Open-market sale | Class A Ordinary Shares | 32,408 | $54.11 footnote F2 | $1.75M | |
| Christopher Hite - Officer | Open-market sale | Class A Ordinary Shares | 117,592 | $54.47 footnote F3 | $6.41M | |
| ||||||
| Elizabeth H. Weatherman - Director | Grant or award | Class A Ordinary Shares | 4,545 footnote F1 | $0.00 | - | |
| ||||||
| Gregory Norden - Director | Grant or award | Class A Ordinary Shares | 4,545 footnote F1 | $0.00 | - | |
| ||||||
| Ted W. Love - Director | Grant or award | Class A Ordinary Shares | 4,545 footnote F1 | $0.00 | - | |
| ||||||
| David C. Hodgson - Director | Grant or award | Class A Ordinary Shares | 4,545 footnote F1 | $0.00 | - | |
| ||||||
| Carole Ho - Director | Grant or award | Class A Ordinary Shares | 4,545 footnote F1 | $0.00 | - | |
| ||||||
| Grant or award | Class A Ordinary Shares | 4,545 footnote F1 | $0.00 | - | ||
| ||||||
| Vlad Coric - Director | Grant or award | Class A Ordinary Shares | 4,545 footnote F1 | $0.00 | - | |
| ||||||
| Bonnie L. Bassler - Director | Grant or award | Class A Ordinary Shares | 4,545 footnote F1 | $0.00 | - | |
| ||||||
| Terrance P. Coyne - Officer | Open-market sale | Class A Ordinary Shares | 64,399 | $53.98 footnote F2 | $3.48M | |
| ||||||
| Marshall Urist - Officer | Open-market sale | Class A Ordinary Shares | 13,684 | $52.75 footnote F2 | $722K | |
| ||||||
| Marshall Urist - Officer | Open-market sale | Class A Ordinary Shares | 13,684 | $53.06 footnote F2 | $726K | |
| ||||||
| Gregory Norden - Director | Open-market sale | Class A Ordinary Shares | 3,045 | $53.00 | $161K | |
| Grant or award | Class A Ordinary Shares | 143,821 footnote F1 | $0.00 | - | ||
| ||||||
| Terrance P. Coyne - Officer | Grant or award | Class A Ordinary Shares | 24,263 footnote F1 | $0.00 | - | |
| ||||||
| Christopher Hite - Officer | Grant or award | Class A Ordinary Shares | 24,263 footnote F1 | $0.00 | - | |
| ||||||
Recent RPRX Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Urist Marshall | Officer | 4,126 | $236K | View on EDGAR | |
| Urist Marshall | Officer | 4,126 |
RPRX insider trading FAQ
What is the latest insider trade for RPRX?
Royalty Pharma plc (RPRX) had 10 insider filings in the last 90 days, with the most recent on 2026-10-05. The full record for RPRX runs to 69 Form 4 filings, the earliest from 2025-05-13. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying RPRX stock?
No insider purchases of RPRX were filed in the last 90 days.
How many insiders are selling RPRX stock?
7 insider sales of RPRX were filed in the last 90 days, totaling $12.97M.
Where can I see RPRX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects RPRX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Marshall Urist view on EDGAR
- - Bonnie L. Bassler view on EDGAR
- - Marshall Urist view on EDGAR
- - Christopher Hite view on EDGAR
- - Christopher Hite view on EDGAR
- - Terrance P. Coyne view on EDGAR
- - Pablo G. Legorreta view on EDGAR
- - Terrance P. Coyne view on EDGAR
- - Christopher Hite view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where RPRX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow RPRX with a 7-day demo
- RPRX on your watchlist
- Every RPRX Form 4 filing on record
- Up to 3 months of RPRX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive